Company intelligence / Profile preview

Vorna

London, United Kingdomvorna.fi ↗

Ownership: Private
Development stage: Other

Overview

Ohtuvayre® (ensifentrine), an inhaled dual PDE3/PDE4 inhibitor developed by Verona Pharma, became the first novel treatment advance in COPD in over a decade when it was FDA-approved in June 2024. It generated $42 million sales in its launch year with strong refill rates and broad prescriber adoption. Clinical trials demonstrated both bronchodilator and anti-inflammatory effects. Additional programs are advancing through Phase II trials targeting NCFBE, CF, and asthma.

Therapeutic areas: Pulmonology
Modalities: Small moleculeInhaled therapyDual phosphodiesterase inhibitor
Industry: Biotech

Beyond the preview

Go deeper on Vorna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vorna.

Explore the full profile